Page 13 - Reflections_dyslipidaemia_newsletter4_2023

REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #4 2023

ADDITIONAL ARTICLES OF INTEREST Dyslipidaemia

1. Relationship of low-density lipoprotein-cholesterol and lipoprotein(a) to cardiovascular risk: The Multi-Ethnic Study
of Atherosclerosis (MESA). Rikhi R, et al. Atherosclerosis. 2022;363:102-108.

2. Cardiovascular disease onset in old people with severe hypercholesterolemia. Coutinho ER, et al. Atherosclerosis.
2023;365:9-14.
3. Association of incident cardiovascular disease with time course and cumulative exposure to multiple risk factors.
Domanski MJ, et al. J Am Coll Cardiol. 2023; 81(12):1151-1161.

4. Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men
in 21 high-income, middle-income, and low-income countries: An analysis of the PURE study. Walli-Attaei M, et al.
Lancet. 2022;400(10355):811-821.

5. Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the
National Lipid Association. Warden BA, et al. J Clin Lipidol. 2023;17(1):19-39.

6. Statin therapy for primary prevention in men: What is the role for coronary artery calcium? Grundy SM, et al. J Clin
Lipidol. 2023;17(1):12-18.
7. Global, regional and national trends in statin utilisation in high-income and low/middle-income countries, 2015-
2020. Guadamuz JS, et al. BMJ Open. 2022;12(9):e061350.

8. Use of statins and other lipid-modifying agents across pregnancy: A nationwide drug utilization study in Norway in
2005-2018. Christensen JJ, et al. Atherosclerosis. 2023;368:25-34.

9. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: A
collaborative analysis of three randomised trials. Ridker PM, et al. Lancet. 2023;401(10384):1293-1301.

10. Lipid-lowering therapy and the risk of dementia: Lessons learned from two decades of controversy. Gebhard C, et
al. Eur Heart J. 2023;44(21):1855-1857.

11. Inclisiran and cardiovascular events: A patient-level analysis of phase III trials. Ray KK, et al. Eur Heart J.
2023;44(2):129-138.
12. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. Das Pradhan A, et al. N Engl J Med.
2022;387(21):1923-1934.

13. Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes. Lacaze P, et al. J Am
Coll Cardiol. 2022;80(14):1287-1298.

14. Are dietary supplements beneficial in lowering cholesterol? SPORT reflections and the path forward. Laffin LI, et al.
Eur Heart J. 2023;44(8):638-640.

15. Effectiveness of medical nutrition therapy in the management of adult dyslipidemia: A systematic review and meta-
analysis. Mohr AE, et al. J Clin Lipidol. 2022;16(5):547-561.

TABLE OF CONTENTS